Real world insights for psoriasis: the association of severity of skin lesions with work productivity, medical consumption costs and quality of life

References

• Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006;155(4):1–8. doi: 10.1111/j.1365-2133.2006.07405.x.
   Web of Science ®Google Scholar
• Augustin M, Blome C, Paul C, et al. Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):294–303. doi: 10.1111/jdv.13823.
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401–407. doi: 10.1016/s0190-9622(99)70112-x.
   PubMed Web of Science ®Google Scholar
• Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. doi: 10.1136/bmj.m1590.
   PubMed Web of Science ®Google Scholar
• AlQassimi S, AlBrashdi S, Galadari H, et al. Global burden of psoriasis - comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol. 2020;59(5):566–571. doi: 10.1111/ijd.14864.
   PubMed Web of Science ®Google Scholar
• Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651–658. doi: 10.1001/jamadermatol.2014.3593.
   PubMed Web of Science ®Google Scholar
• Villacorta R, Teeple A, Lee S, et al. A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis. Br J Dermatol. 2020;183(3):548–558. doi: 10.1111/bjd.18798.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Schupp C, Wu J, et al. Quality of life and work productivity impairment among psoriasis patients: findings from the national psoriasis foundation survey data 2003-2011. PLOS One. 2012;7(12):e52935. doi: 10.1371/journal.pone.0052935.
   PubMed Web of Science ®Google Scholar
• Bronckers I, van Geel MJ, van de Kerkhof PCM, et al. A cross-sectional study in young adults with psoriasis: potential determining factors in quality of life, life course and work productivity. J Dermatolog Treat. 2019;30(3):208–215. doi: 10.1080/09546634.2018.1506077.
   PubMed Web of Science ®Google Scholar
• Korman NJ, Zhao Y, Pike J, et al. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin Exp Dermatol. 2016;41(5):514–521. doi: 10.1111/ced.12841.
   PubMed Web of Science ®Google Scholar
• Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432–470. doi: 10.1016/j.jaad.2020.07.087.
   PubMed Web of Science ®Google Scholar
• (NVDV) NVvDeV. Richtlijn psoriasis. 2024. https://richtlijnendatabase.nl/richtlijn/psoriasis/startpagina_-_psoriasis2.html
   Google Scholar
• Armstrong AW, Siegel MP, Bagel J, et al. From the medical board of the national psoriasis foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290–298. doi: 10.1016/j.jaad.2016.10.017.
   PubMed Web of Science ®Google Scholar
• Bruins FM, Bronckers I, Groenewoud HMM, et al. Association between quality of life and improvement in psoriasis severity and extent in pediatric patients. JAMA Dermatol. 2020;156(1):72–78. doi: 10.1001/jamadermatol.2019.3717.
   PubMed Web of Science ®Google Scholar
• Heydendael VM, de Borgie CA, Spuls PI, et al. The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc. 2004;9(2):131–135. doi: 10.1111/j.1087-0024.2004.09115.x.
   PubMedGoogle Scholar
• Salgado-Boquete L, Carrascosa JM, Llamas-Velasco M, et al. A new classification of the severity of psoriasis: what’s moderate psoriasis? Life. 2021;11(7):627. doi: 10.3390/life11070627.
   PubMedGoogle Scholar
• Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the national psoriasis foundation surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180–1185. doi: 10.1001/jamadermatol.2013.5264.
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–365. doi: 10.2165/00019053-199304050-00006.
   PubMed Web of Science ®Google Scholar
• Noben CY, Evers SM, Nijhuis FJ, et al. Quality appraisal of generic self-reported instruments measuring health-related productivity changes: a systematic review. BMC Public Health. 2014;14(1):115. doi: 10.1186/1471-2458-14-115.
   PubMedGoogle Scholar
• iMTA. Manual iMTA Medical Cost Questionnaire (iMCQ). 2024. https://www.imta.nl/questionnaires/imcq/#:∼:text=The%20iMTA%20Medical%20Consumption%20Questionnaire,is%20therefore%20not%20disease%20specific
   Google Scholar
• Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol group. Ann Med. 2001;33(5):337–343. doi: 10.3109/07853890109002087.
   PubMed Web of Science ®Google Scholar
• Versteegh MM, Attema AE, Oppe M, et al. Time to tweak the TTO: results from a comparison of alternative specifications of the TTO. Eur J Health Econ. 2013;14(Suppl 1):S43–S51. doi: 10.1007/s10198-013-0507-y.
   PubMedGoogle Scholar
• Shikiar R, Bresnahan BW, Stone SP, et al. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes. 2003;1(1):53. doi: 10.1186/1477-7525-1-53.
   PubMedGoogle Scholar
• Yang Y, Brazier J, Longworth L. EQ-5D in skin conditions: an assessment of validity and responsiveness. Eur J Health Econ. 2015;16(9):927–939. doi: 10.1007/s10198-014-0638-9.
   PubMed Web of Science ®Google Scholar
• Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: delphi consensus from the international psoriasis council. J Am Acad Dermatol. 2020;82(1):117–122. doi: 10.1016/j.jaad.2019.08.026.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Lin CY, Goldblum O, et al. Efficacious psoriasis treatment improves patients’ work productivity. J Eur Acad Dermatol Venereol. 2020;34(10):e593–e596. doi: 10.1111/jdv.16457.
   PubMed Web of Science ®Google Scholar
• Saeki H, Kanai Y, Murotani K, et al. Work productivity in real-life employed patients with plaque psoriasis: results from the ProLOGUE study. J Dermatol. 2022;49(10):970–978. doi: 10.1111/1346-8138.16517.
   PubMed Web of Science ®Google Scholar
• Igarashi A, Yuasa A, Yonemoto N, et al. A systematic literature review of economic evaluations and cost studies of the treatment of psoriasis, atopic dermatitis, and chronic urticaria. Dermatol Ther. 2022;12(8):1729–1751. doi: 10.1007/s13555-022-00774-2.
   Web of Science ®Google Scholar
• Belinchón Romero I, Dauden E, Ferrándiz Foraster C, et al. Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document. Ann Med. 2021;53(1):1727–1736. doi: 10.1080/07853890.2021.1986637.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Levin AA, Armstrong AW, et al. The international dermatology outcome measures group: formation of patient-centered outcome measures in dermatology. J Am Acad Dermatol. 2015;72(2):345–348. doi: 10.1016/j.jaad.2014.11.002.
   PubMed Web of Science ®Google Scholar
• van Muijen ME, Atalay S, van Vugt LJ, et al. Unmet personal patient needs in psoriasis patients with low disease activity on adalimumab, etanercept or ustekinumab. Drugs Real World Outcomes. 2021;8(2):163–172. doi: 10.1007/s40801-021-00227-w.
   PubMedGoogle Scholar
• van den Reek J, Seyger MMB, van Lumig PPM, et al. The journey of adult psoriasis patients towards biologics: past and present – Results from the BioCAPTURE registry. J Eur Acad Dermatol Venereol. 2018;32(4):615–623. doi: 10.1111/jdv.14684.
   PubMed Web of Science ®Google Scholar
• Driessen RJ, Bisschops LA, Adang EM, et al. The economic ­impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol. 2010;162(6):1324–1329. doi: 10.1111/j.1365-2133.2010.09693.x.
   PubMed Web of Science ®Google Scholar
• CBS. Ruim 1,2 miljoen Nederlanders hebben eczeem of psoriasis. 2024. https://www.cbs.nl/nl-nl/nieuws/2015/46/ruim-1-2-miljoen-nederlanders-hebben-eczeem-of-psoriasis
   Google Scholar
• Nowowiejska J, Baran A, Flisiak I. Mutual relationship ­between sleep disorders, quality of life and psychosocial aspects in ­patients with psoriasis. Front Psychiatry. 2021;12:674460. doi: 10.3389/fpsyt.2021.674460.
   PubMed Web of Science ®Google Scholar